G12d
Untracked preview. This is not a tracked Signal Bureau entity — the page is generated on request from live coverage search, is not indexed, and carries no editorial curation. Tracked entities live on the Wire.
If G12d is on your watch list: what changed in the coverage, what the reporting asserts, and what the crowd is pricing.
What’s changed
- Targeted therapeutic strategies for KRAS-G12D-mutant non-small cell lung cancer: a narrative review. · Transl Lung Cancer Res · 2026-07-20
- [Development of Therapies Targeting Non-G12C KRAS Mutations (Focusing on G12D and Pan-RAS)]. · Gan To Kagaku Ryoho · 2026-07-01
- JinFang Pharma's Oral Drug GFH375 Enters Phase III Lung Cancer Trial, Challenging Difficult KRAS G12D Target - finance.biggo.com · KRAS Mutation Research (Google News) · 2026-08-10 · usually covers Kras Research
- Genfleet becomes first to test oral KRAS G12D inhibitor in Phase III for NSCLC - AllSci · KRAS Mutation Research (Google News) · 2026-08-10 · usually covers Kras Research
- GenFleet Advances Second Phase III Trial for Oral KRAS G12D Lung Cancer Drug - TipRanks · KRAS Mutation Research (Google News) · 2026-08-10 · usually covers Kras Research
- Anirban Maitra: Clinical Trial Explores KRAS G12D-Mutated Solid Tumor Treatment - Oncodaily · KRAS Mutation Research (Google News) · 2026-08-02 · usually covers Kras Research
What the reporting says
It shows up alongside KRAS (57), Colorectal Cancer (14), Pancreatic Cancer (13).
Two steps out: Pdac (through KRAS, 18 shared stories on the weaker link); Braf (through KRAS, 17 shared stories on the weaker link); Immunotherapy (through KRAS, 17 shared stories on the weaker link); ctDNA (through KRAS, 15 shared stories on the weaker link).
Tracked since Apr 12, with coverage on 42 separate days — concentrated in Oncology and Pubmed Targeted.